Publications by authors named "N Miriyala"

Claim this Profile
R
RALGEF inhibitors suppress RAS-driven pancreatic cancer and metastasis.
Howard Donninger, Rachel Ferrill, Becca von Baby, Katie R Hobbing, William L Dean, Nagaraju Miriyala

J Biol Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft Model.
James C Tarr, Kyuok Jeon, Nagarathanam Veerasamy, Martin Aichinger, James M Salovich, Nagaraju Miriyala

J Med Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent Activities in Mouse Models of Hematological and Solid Tumors.
James C Tarr, James M Salovich, Martin Aichinger, KyuOk Jeon, Nagarathanam Veerasamy, Nagaraju Miriyala

J Med Chem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors.
Wieslaw M Kazmierski, Nagaraju Miriyala, David K Johnson, Sam Baskaran

ACS Med Chem Lett· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.
Wieslaw M Kazmierski, Sam Baskaran, Jill T Walker, Nagaraju Miriyala, Ramu Meesala

J Med Chem· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis